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Abstract
Background: Systemic embolism is a serious and sometime fatal complication of rheumatic MS.
Objective: We assessed the predictive power of  D-Dimer level to predict occurrence of  left atrial (LA) thrombi in patients
with rheumatic mitral stenosis (MS).
Methods: D-dimer levels were analyzed for 24 patients with rheumatic MS with LA clot and 22 patients with rheumatic MS
with no LA clot undergoing transeosophageal echocardiography.  A level more than 4 µg/ml was taken as elevated to predict
the presence of LA clot in the study groups.
Results:  For a cut-off  value of  4 µg/ml, sensitivity was 66.67 % and specificity 100 % for prediction of  LA clot and AUC
0.710. A cut-off value of less than 1 µg/ml, sensitivity was 91.67 % and 87. 5 % negative predictive value for ruling out
presence of  LA clot and AUC 0.721.
Conclusions: A higher value of D-dimer can predict the possible presence of a LA clot and very low value can predict
absence of clot in patients with rheumatic MS.
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Introduction
Systemic embolism is a serious and sometime fatal
complication of  rheumatic MS.1 A large body of
evidence indicates that patients with MS are at
increased risk of developing left atrial thrombus and
the associated thromboembolic complications. Part
of this risk may be attributed to the hypercoagulable
state associated with atrial fibrillation (AF),2 but there
have  been studies that systemic coagulation activity
is increased in MS per se.3-6. Transthoracic
echocardiography (TTE), although easily performed,
is an insensitive tool to detect clots because the left
atrial appendage (LAA) cannot be easily visualized.
Transesophageal echocardiography (TEE) is more
useful to diagnose thrombus in the LAA. The
importance of documenting the presence of LA
thrombus clinically is highly relevant, as these patients
who have clots are thus at a high risk of cardiac
thromboembolism.
Measurement of fibrin D-dimer levels has been
advocated as a useful clinical marker of
thrombogenesis.7 The use of  D-dimer levels in the
investigation and management pathway of venous
thromboembolism is well established.8-9 This marker
has a high sensitivity and specificity in excluding
thromboembolism when a well-defined assay is used
in the appropriate clinical setting. As is in the case of
venous thromboembolism, a negative D-dimer may
be used to exclude atrial thrombus and perhaps to
decide on the need for anticoagulation in patients
with rheumatic mitral valve disease irrespective of
the clinical risk factors which is less sensitive for
clinical decision making.
Few studies in patients with rheumatic MS
have focused on D-dimer levels for prediction of
left atrial thrombus in patients undergoing balloon
mitral valvuloplasty.10-11 Hence, we designed this
prospective study to investigate these issues. Because
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D-dimers are of particular use in cardiovascular
disease due to their role in detecting the presence of
thrombus or clot, we hypothesize that increased D-
dimer level in Indian patients with valvular heart
disease suggest the presence of  intra-cardiac clot and
hence the need for anticoagulation and
contraindicated for balloon mitral valvotomy
irrespective of the clinical predictors of embolic risk.
It can also be possible that D-dimer level can be
used as guide on the intensity of anticoagulation
needed to minimize thrombogenesis.
Methods
46 patients with symptomatic rheumatic MS
undergoing transeosophageal echocardiography
(TEE) before percutaneous transmitral
commissurotomy (PTMC) from G.B.Pant Hospital,
New Delhi, India constituted the study population.
The study protocol was approved by the hospital
ethics committee and all patients and controls
voluntarily gave informed consent. Those with left
atrial clot in TTE, suspected left atrial clot or where
the LA appendage was not clear on TTE underwent
a TEE before PTMC procedure. 24 patients with
rheumatic MS with left atrial clot on TEE formed
the study population (Group A). Control group
include 22 patients with rheumatic MS with no left
atrial clot on TEE (Group B). Patients with the
following were excluded from the study: (a) patients
with inadequate TEE examination, (b) patients with
renal failure, (c) patients with hepatic impairment,
(d) acute or chronic infection and (e) neoplastic
disease. None of the patients in the study population
had stroke or peripheral vascular disease.
Detailed clinical history was taken for all
patients and clinical examination was performed in
all patients and controls. (Groups A and B). Five ml
of blood was collected from the study group as
well as from the control group for the D-Dimer
assay under standard conditions. Five ml of  blood
was collected into sodium citrate bottles and
centrifuged at 3000 rpm for 20 minutes to obtain
plasma. D-Dimer levels were estimated from
plasma, using commercially available ELISA kits
from Gen Way Biotech, San Diego, California, USA.
and expressed in µg/ml.13
A D-dimer level more than 4µg/ml was
considered as high and used to differentiate those
with and without LA clot on TEE and to assess
whether there is significant difference between two
groups. The sensitivity, specificity, positive predictive
value, negative predictive value, and accuracy of D-
Dimer assay are determined using presence of  clot
in TEE as a gold standard. A subgroup analysis
included comparison of D-Dimer assay in patients
with sinus rhythm and atrial fibrillation in the study
group.
Statistical analysis
To summarise the data obtained, continuous
variables were expressed as mean ± standard
deviation and discrete variables were expressed as a
percentage. Statistical analyses were performed with
SPSS version 13 (SPSS Inc). Continuous variables
were compared by Student’s t-test. The independent
predictive role of embolic predictors were evaluated
by multiple regression analysis of the baseline
parameters. The sensitivity, specificity, positive
predictive value, negative predictive value and
accuracy of D-Dimer level for the presence of
thrombus was calculated using standard formulas.
Statistical significance was ascribed, when p<0.05.
The receiver operating characteristic (ROC) curves
were constructed using STATA software.
Results
There were 24 patients in group A (with LA clot)
and 22 patients in group B (control group).There
were 7 males and 17 females in the test group and 8
males and 14 females in the control group. The mean
age of the population was 33 years (15-60 years) in
the test group and 26 years (18-42 years) in the control
group. In group A 20 patients were in atrial
fibrillation and 4 in sinus rhythm. In group B 15
patients were in sinus rhythm and 7 patients were in
atrial fibrillation.  The baseline characteristics of both
the groups were given in table 1.
The D-dimer values were measured in
ranges of 0.5 -1, 1-2,  2-4, 4-8, and more than 8
µg/ml  in all these patients. The D-dimer levels were
more than 4 µg/ml in 16 patients in group A.  Eight
patients had value less than 4µg/ml. All patients who
had a D-Dimer value of more than 4µg/ml had a
clot in the LA. In the control group (group B), none
of the patients had D-dimer level more than 8µg/
ml. All the patients had D-dimer level less than 4
µg/ml and in 14 patients, the values were less than 1
µg/ml. Eight patients had value between 1 and 4
µg/ml. LA size, MVA, mean gradient, and
Pulmonary artery pressures were not different in
patients with and without LA clot. The range of D-
Dimer levels in all the patients in the study population
are given in table 2.
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Table 1: Baseline characteristics of  the study population
Group A (n=24) Group B (n=22) p value
Age (mean ±SD) 33 ±13.62 26 ± 7.12
Sex M/F 7/17 8/14
AF 20 7
MVA 0.875±0.113 0.94±0.156 0.11
Mean gradient 16 ±4.52 14.86 ±3.68 0.35
LA size 4.68±0.56 4.42±0.49 0.10
PA pressure 52.66±15.43 52.21 ±17.64 0.92
Table 2: D- dimer levels in the different range
in the study population
D-dimer levels Group  A     Group B
                                 (n=24)         (n=22)
0.5 -1 µg/ml 2 14
1-2 µg/ml 3 0
2-4 µg/ml 3 8
4-8 µg/ml 13 0
>8 µg/ml 3 0
Receiver operating characteristic (ROC) curve for
D-dimer levels was plotted by applying logistic
regression to determine the cut-off  having the highest
sensitivity as well as specificity (figures 1 and 2
respectively). The sensitivity, specificity, positive and
negative predictive values were calculated for
different cut-off  values for D-Dimer levels. When a
cut-off value of 4 µg/ml was taken, the sensitivity
was 66.67 % and specificity 100 % for the prediction
of LAA clot. A cut-off value of less than 1 µg/ml
has high sensitivity of 91.67 % and 87. 5 % negative
predictive value for ruling out the presence of LAA
clot. Area under ROC curve was 0.710 (95 % CI:
0.558- 0.834) for a cut-off value of 4 µg/ml for
the prediction of LAA clot and 0.721 (95% CI: 0.569
– 0.843) for a cut-off value of 1µg/ml for ruling
out the presence of  LAA clot. The sensitivity,
specificity, predictive values, and area under ROC
were for different cut-off values of D-Dimer are
given in table 3 and ROC curves for cut-off  values
of 4µg/ml and 1µg/ml are given in figures 1 and 2.
Table 3 : Sensitivity, specificity, positive predictive value, negative predictive value for different
cut-off values for D-Dimer levels
Cut-off Sensitivity Specificity Positive   Negative Area under     95 % CI
                                                           PV             PV            ROC
4 µg/ml 66.67% 100% 100% 73.3% 0.710 0.558-0.834(p=0.003)
2 µg/ml 79.1% 63.64% 70.37% 73.68% 0.628 0.569-0.843 (p=0.12)
1 µg/ml 91.67% 63.64% 73.35 87.5% 0.628 0.473-0.765 (p=0.01)
Figure 1: The sensitivity and Specificity and area
under ROC for cut-off value for D-dimer level
of 4µg/ml
Figure 2: The sensitivity, specificty and area
under ROC for cut-off level for D-dimer level
of 1µg/ml
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Discussion
In the present study we analyzed D-dimer level as a
non-invasive marker for the prediction of left atrial
thrombus in North Indian patients with rheumatic
MS undergoing PTMC. In the present study D-
dimer levels were high in patients with left atrial
appendage clot and a level more than 4 µg/ml has
100% specificity and positive predictive value for
the presence of LAA clot. A value of less than 1
µg/ml has very high sensitivity and negative predictive
value for ruling out LAA clot in this group of
patients.
Several clinical trials have indicated that
patients with MS are at increased risk of devoloping
left atrial thrombus and it may be attributed to the
state of hypercoagulability associated with
abnormalities of  hemostasis, platelets and endothelial
dysfunction.3-6. Having a marker of coagulation
activation would be useful in identifying patients at
highest thromboembolic risk, who might benefit
most from anti-thrombotic therapy. Biomarkers of
hypercoagulability, such as D-dimer, indicative of  a
prothrombotic state, can be used to predict those
who are at increased risk of thromboembolism.
D-dimers originate from the formation and
lysis of cross-linked fibrin and are therefore specific
markers of activation of coagulation. D-dimer levels
may be increased as a result of co-morbid conditions
causing intravascular or extravascular cross-linked
fibrin turnover such as in renal failure, liver
impairment, acute or chronic infection, neoplastic
disease, hypertension, acute cardiovascular or
cerebrovascular syndromes, bleeding, haematoma,
and surgery.8 The interpretation of  D-dimer levels
can therefore be considered as reflecting the pro-
thrombogenic state of patients without these acute
clinical conditions and without overt thrombosis.
Thrombus formation is a process involving platelets
adherence to the vessel wall, platelet aggregation,
thrombin generation and fibrin formation. As fibrin
D-Dimer is considered to originate from cross-
linked fibrin assembled during thrombus formation,
a rise in fibrin D-Dimer level is indicative of
thrombus formation.8,9
Systemic thromboembolism is a serious
complication in patients with valvular heart disease
and its incidence is highest in those with MS. The
status of fibrin generation and fibrinolysis in the
peripheral blood of patients with MS has been
studied by several groups. Yasaka et al 10 reported
that levels of fibrinopeptide A, D-Dimer, and
antithrombin III in the peripheral blood were
significantly higher in patients with MS than in normal
subjects. Wang et al 11 reported that patients with
MS who were in sinus rhythm showed a significant
increase in the D-Dimer level in the peripheral blood,
when compared with control subjects; suggesting
that the coagulation system is activated in patients
with MS .
It has been suggested that the measurement
of plasma fibrin D-Dimer concentration may be a
useful screening method for patients at risk for
intracardiac thrombi and hence
thromboembolism.12,13  This was demonstrated in a
prospective study of  63 patients with MS, in whom
a significantly elevated plasma D-Dimer level was
found in 10 patients with mobile intracardiac
thrombus, when compared with patients with non-
mobile thrombus or no thrombus.  Umemeto et al
14 examined the clotting and fibrinolytic activity in
37 patients with intracardiac thrombi. Plasma D-
Dimer level was found to be positively related to
clotting activity. If  an excess of  thrombosis over
fibrinolysis was present, there was a substantial risk
of arterial embolisation
Somoloi et al 15 studied D-Dimer level in
75 patients undergoing electrical cardioversion in
patients with atrial fibrillation and suggested that
serum D-Dimer level is a useful marker of overall
embolic risk in patients with atrial fibrillation and
reflect a cumulative prothrombotic effect of clinical
and echocardiographic predictors of stroke. D-
dimer level as a single test adequately defined low
thromboembolic risk associated with cardioversion
of  AF in two-third of  patients. Habara et al16
measured D-dimer level in 925 patients with non-
valvular atrial fibrillation undergoing TEE, which
detected 83 LAA thrombus and yielded a  negative
predictive value of 97% for identifying LAA
thrombus for a cut-off  value of  D-dimer. D-dimer
levels have been shown to be increased in AF
especially in patients having multiple risk factors for
embolism in earlier studies17,18. Ibebuogu et al18
described a case where elevated D-dimer resulted
in performance of  TEE, which documented atrial
thrombus in a patient with infective endocarditis, atrial
fibrillation and pulmonary edema and saved the
patient from complications of cardioversion, which
should have resulted from emergency cardioversion.
Even the presence of a high D-dimer level is a strong
predictor of  survival in patients with chronic atrial
fibrillation.
Low levels of D-dimer seen in patients with
rheumatic MS with LA clot could be due to the
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effect of warfarin on reducing the levels of D-dimer
as reported by some investigators early.19,20 In the
present study, patients with rheumatic MS in our study
were not on anti-coagulant (warfarin) therapy. If  LA
clot was detected by TTE/TEE in patients with
rheumatic MS (Group A), D-dimer estimation was
done first and then, the patient was started on
anticoagulants, hence this would not affect their D-
dimer levels. The control group (Group B) did not
need anti-coagulant therapy.
Study limitations
Firstly, a small sample size was a major limitation in
this study. Secondly, number of  patients with atrial
fibrillation were not comparable in the two groups.
Patients with AF were higher in group A, compared
to group B. Some elevation of  D-dimer could be
due to persistent atrial fibrillation and the elevation
of D-dimer in patients without LAA clot could also
be due to patients with atrial fibrillation in this group.
We included consecutive patients undergoing TEE
before mitral valvuloplasty and our aim was to find
out a non-invasive marker which could predict or
rule out the presence of  LA clot in this patients. If
we had included patients with atrial fibrillation only,
the interpretation should have been much easier, but
the clinical utility of this test in an unselected patient
group undergoing PTMC might have been less.
However we need prospective validation of this
different cut-off level of D-dimer in predicting LA
clot in consecutive patients undergoing TEE, in
studies involving a larger study population, before
widespread clinical use.
Conclusion
D-dimer levels were high in patients with left atrial
appendage clot. In this group of patients, a level of
D-dimer more than 4 µg/ml had 100% specificity
and positive predictive value for the presence of
LAA clot. A value of less than 1 µg/ml had very
high sensitivity and negative predictive value for ruling
out LAA clot in this group of  patients. Higher value
of D-dimer could predict the possible presence of
a LAA clot and very lower values of D-dimer could
predict the possible absence of LAA clot in patients
who were considered for PTMC, irrespective of
the rhythm, LA size, mitral valve area, pulmonary
artery pressure and mitral valve gradient. To the best
of our knowledge, there are very few studies which
demonstrate the above correlation in Indian patients
with MS.
Patients with MS who were detected to have
LA clot by TEE before PTMC, the serum level of
D-dimer were higher, compared to MS patients
without LA clot. All patients who had a D-Dimer
value of more than 4 µg/ml had a clot in the LA,
while none of the patients without clot had such a
value.  Majority of the patients without LA clot had
D-dimer level less than 1 µg/ml and all the patients
had value less than 4 µg/ml. So a higher value of
D-dimer can be used to predict the possible presence
of a clot and very low value of D-dimer can be
used to predict the absence of clot in patients with
rheumatic MS, who are considered for PTMC,
irrespective of the rhythm, LA size, mitral valve area,
pulmonary artery pressure and mitral valve gradient.
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